Gossamer Bio, INC

Gossamer Bio announced it has regained compliance with Nasdaq's minimum bid price requirement, closing a previously identified deficiency.

Gossamer Bio announced the submission of its first New Drug Application (NDA) to the FDA for seralutinib, a treatment for pulmonary arterial hypertension (PAH), marking a key regulatory step.

Gossamer Bio announced the appointment of Greg Ciongoli, Founder and Managing Partner of Adiumentum Capital Management, to its Board of Directors and Audit Committee, effective September 16, 2026.

Gossamer Bio announced the effectiveness of its 1-for-80 reverse stock split and a reduction in authorized shares, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Gossamer Bio, Inc. is implementing a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with shares expected to trade on a split-adjusted basis starting September 11, 2026.

Gossamer Bio, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of outstanding voting stock.

Gossamer Bio announced the reacquisition of global rights to seralutinib from Chiesi, alongside a significant debt restructuring and a substantial net loss for the quarter.

Gossamer Bio reported a significant increase in net loss for the nine months ended September 30, 2025, despite progress in its seralutinib clinical programs and ongoing collaboration revenue.

Gossamer Bio, a late-stage biopharmaceutical company, reported a significant net loss and increased cash burn in Q2 2025, driven by higher research and development expenses for its lead candidate seralutinib.

Gossamer Bio reports a net loss of $36.6 million for Q1 2025, with revenue driven by the Chiesi collaboration and ongoing development of Seralutinib.

Gossamer Bio's third quarter 2024 results show a net loss of $30.8 million, but also include significant revenue from a collaboration agreement.

Gossamer Bio announced a profitable second quarter of 2024, driven by a significant collaboration agreement with Chiesi, while also detailing ongoing clinical development and financial updates.

Gossamer Bio announced a workforce reduction and missed the primary endpoint in its Phase 3 PROSERA trial for seralutinib, leading to strategic re-evaluation and a need for additional capital.

Gossamer Bio's 2024 10-K filing details the company's focus on seralutinib for pulmonary hypertension, its collaboration with Chiesi, and ongoing clinical trials.

Gossamer Bio's 2023 10-K filing highlights the company's focus on developing seralutinib for pulmonary hypertension, including ongoing Phase 3 trials and future plans for PH-ILD.

Thomas O Daniel, a Director of Gossamer Bio, Inc., received 10,000 shares of common stock on September 23, 2026.

Gregory Austin Ciongoli, a Director of Gossamer Bio, Inc., received 30,000 shares of common stock on September 23, 2026.

Skye Drynan, a Director of Gossamer Bio, Inc., received 10,000 shares of common stock on September 23, 2026.

John D Quisel, a Director of Gossamer Bio, Inc., received 10,000 shares of common stock on September 23, 2026.

Russell J. Cox, a Director of Gossamer Bio, Inc., received 10,000 shares of common stock on September 23, 2026.

Waage Christian, EVP, Tech Ops and Admin of Gossamer Bio, Inc., received 2,900,026 shares of common stock on August 24, 2026.

Gossamer Bio is holding a special meeting to seek stockholder approval for the potential issuance of common stock related to a private placement, including shares for executive officers and directors.

Gossamer Bio is holding a special meeting of stockholders to vote on several proposals, including an exchange offer for its convertible notes, an amendment to its incentive award plan, and an increase in authorized shares.

Gossamer Bio, Inc. has issued its 2026 proxy statement detailing director elections, executive compensation, and auditor ratification for the upcoming annual meeting.

Gossamer Bio is holding its annual meeting and seeking shareholder ratification of Ernst & Young LLP as its independent auditor for the year ending December 31, 2020.

Gossamer Bio sets June 25, 2025, for its annual stockholder meeting and proposes an amendment to its 2019 Incentive Award Plan.

Gossamer Bio is holding its annual meeting and seeking shareholder ratification of Ernst & Young LLP as its independent auditor for the year ending December 31, 2020.

D.E. Shaw entities have filed an amendment to their Schedule 13D regarding Gossamer Bio, Inc., detailing share ownership adjustments and a joint filing agreement.

D. E. Shaw entities have collectively reduced their beneficial ownership in Gossamer Bio, Inc. to 6.0% through a series of sales between late July and late August 2026.

D. E. Shaw entities have filed an amendment to their Schedule 13D, reporting a combined beneficial ownership of 7.1% of Gossamer Bio, Inc. common stock.

D.E. Shaw entities report transactions in Gossamer Bio common stock over the past 60 days, with significant net sales.

D. E. Shaw & Co. reports a 9.5% beneficial ownership stake in Gossamer Bio following a debt-for-equity exchange offer.

Growth Equity Opportunities 18 VGE, LLC and affiliated entities have significantly reduced their beneficial ownership in Gossamer Bio, Inc. through recent open market sales.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of over 5% of Gossamer Bio, Inc. common stock.

DeepCurrents Investment Group LLC and affiliates have reported a 7.7% beneficial ownership stake in Gossamer Bio, Inc. via a Schedule 13G filing.

683 Capital Management, LLC and Ari Zweiman have reported a 9.99% beneficial ownership stake in Gossamer Bio, Inc. as of June 11, 2026.

Context Capital Management, LLC and its affiliates have reported beneficial ownership of 48,835,788 shares, representing 9.9% of the outstanding common stock of Gossamer Bio, Inc.

Octagon Capital Advisors LP, along with affiliated entities and Ting Jia, has reported beneficial ownership of 8,976,054 shares, representing 3.8% of Gossamer Bio, Inc.'s common stock.

The Vanguard Group has filed an Amendment No. 6 to Schedule 13G, reporting zero beneficial ownership in Gossamer Bio Inc. Common Stock following an internal realignment.